LNAI
Lunai Bioworks Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.47
−30.63%Sep 22, 2026, 13:20 UTC
Lunai Bioworks announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. to add human cellular phenotyping to its Parkinson's disease discovery and validation platform.
Source:Sep 16, 2026, 13:25 UTC
Lunai Bioworks' BioSymetrics subsidiary shared results from a technical case study supporting the development of structure-based screening tools for chemical outputs generated by large language models and other AI systems.
Source:Aug 27, 2026, 13:27 UTC
Lunai Bioworks filed a second amended complaint in its naked short selling lawsuit, adding six broker-dealers as defendants and alleging securities fraud and market manipulation under Rule 10b-5.
Source:Aug 4, 2026, 19:28 UTC
Lunai Bioworks signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027.
Source:Aug 4, 2026, 13:20 UTC
Lunai Bioworks filed an amended complaint in a lawsuit naming 10 defendants for naked short selling fraud, alleging 29.6 million failed-to-deliver shares and seeking treble damages under federal RICO statute.
Source: